Called the AMP study, a ‘landmark,’ multinational clinical trial launched today to test HIV-blocking broadly neutralizing antibodies. VIDD Member Dr. Larry Corey, right, is one of two top HIV researchers chairing the trial. Read more >
Fred Hutch News Service
Understanding anti-viral immunity with Jenny Lund
The immune response to pathogens must be powerful enough to clear the infection but controlled enough to limit the scope of damage. Because an overactive response can result in autoimmune disease or organ transplant rejection, a fine balance is needed to maintain immune system homeostasis.
Cytomegalovirus viral load predicts post-HSCT mortality
After undergoing hematopoietic stem cell transplantation (HSCT), patients are severely immunocompromised. This makes them susceptible to infections that do not normally cause disease in healthy individuals, such as cytomegalovirus (CMV).